Conflicts of interest Dr Strober is a consultant who has received honoraria from AbbVie, Alumis, Almirall, Amgen, Apogee, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Capital One, CorEvitas, Dermavant, Immunovant, Janssen, Leo, Eli Lilly, Maruho, Oruka, Meiji Seika Pharma, Protagonist, Takeda, Novartis, Pfizer, UCB Pharma, Rapt, Regeneron, Sanofi Genzyme, and Union Therapeutics; holds stock options in Connect Biopharma, Mindera Health; has served as a speaker for AbbVie, Arcutis, Dermavant, Eli Lilly, Incyte, Janssen, Regeneron, and Sanofi Genzyme; as a scientific co-director (consulting fee) for CorEvitas Psoriasis Registry; as an investigator for CorEvitas Psoriasis Registry and is the Editor-in-Chief (honorarium) of Journal of Psoriasis and Psoriatic Arthritis. Dr Blauvelt has served as a speaker (received honoraria) for Eli Lilly and Company, UCB, and Almirall, has served as a scientific adviser (received honoraria) for AbbVie, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Corvus, Dermavant, Eli Lilly and Company, Galderma, GlaxoSmithKline, Immunovant, Incyte, IQVIA, Janssen, Leo, Lipidio, Merck, Novartis, Oruka, Paragon, Pfizer, Regeneron, Sanofi, Spherix Global Insights, Sun Pharma, Syncona, Takeda, UCB, and Union, has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Almirall, Alumis, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, and UCB, and owns stock in Lipidio and Oruka. Dr van de Kerkhof received fees for consultancy services or lectureships from Almirall, Eli Lilly, Novartis, Janssen Pharmaceutical, Bristol Myers Squibb, UCB, Boehringer Ingelheim, Centrion, and Sandoz. Dr González-Cantero has served as a consultant for and received speaker fees from AbbVie, Janssen, Novartis, Almirall, Celgene, BMS, UCB, L'Oreal, MSD, and Leo Pharma. Dr El-Kalioby received fees for speaker honoraria from Janssen, Novartis, and Boehringer Ingelheim. Dr Matlock has served as a consultant for and received speaker fees from AbbVie, Janssen, Novartis, Pfizer, L'Oreal, Leo Pharma, Merck Sharp and Dome, Glaxo Wellcome and SmithKline Beecham, Sanofi. Dr Rob has received honoraria as a speaker and/or consultant for AbbVie, Almirall, BMS, Eli Lilly, Johnson & Johnson, Leo Pharma, Novartis, Pfizer, Sanofi Genzyme, and UCB. Dr Asawanonda has received honorarium as a speaker for Boehringer Ingelheim, Eli Lilly, Novartis, Janssen, LEO Pharma, Pfizer, Sanofi, Kyowa Kirin. Beiersdorf, and LaRoche Posay; as a consultancy or advisory board for Boehringer Ingelheim, Eli Lilly, Novartis, Janssen, LEO Pharma, Pfizer, Sanofi, Kyowa Kirin. Beiersdorf, and LaRoche Posay; and as an investigator consultant for Boehringer Ingelheim, Eli Lilly, Novartis, LEO Pharma, Kyowa Kirin, GSK, and Beiersdorf. Dr Maul has served as advisor and/or received speaking fees and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, BMS, Celgene, Eli Lilly, Incyte, Janssen-Cilag, LEO Pharma, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, Takeda, and UCB. Dr Torres has received consultancy and/or speaker's honoraria from and/or participated in clinical trials sponsored by AbbVie, Amgen, Almirall, Amgen, Apogee Therapeutics, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Johnson & Johnson Innovative Medicine, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz, STADA, and UCB. Dr Skov has received research funding from Almirall, UCB, Sanofi, Bristol Myers Squibb, Janssen, the Danish National Psoriasis Foundation, the LEO Foundation, and the Kgl. Hofbundtmager Aage Bang Foundation and honoraria as consultant and/or speaker for AbbVie, Eli Lilly, Novartis, Pfizer, LEO Pharma, Bristol Myers Squibb, Janssen, UCB, Almirall, Galderma, Bristol Myers Squibb, Takeda, Stada, and Sanofi. Drs Gonzalez and Chandra have no conflicts of interest to declare.